azelnidipine has been researched along with deoxyglucose in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, R; Horiuchi, M; Iwai, M; Li, HS; Li, JM; Min, LJ; Mogi, M; Shiuchi, T; Suzuki, J; Tomochika, H; Tomono, Y; Tsuda, M; Wu, L | 1 |
1 other study(ies) available for azelnidipine and deoxyglucose
| Article | Year |
|---|---|
Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites; Antioxidants; Azetidinecarboxylic Acid; Blood Glucose; Calcium Channel Blockers; Cyclic N-Oxides; Deoxyglucose; Diabetes Mellitus, Type 2; Dihydropyridines; Glucose Intolerance; Glucose Tolerance Test; Glucose Transporter Type 4; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Phosphoproteins; Spin Labels; Superoxides; Tetrazoles | 2006 |